董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| David F. Hale | 男 | Executive Chairman | 72 | 10.02万美元 | 未持股 | 2021-04-30 |
| Marsha A. Chandler | 女 | Director | 76 | 3.77万美元 | 未持股 | 2021-04-30 |
| Bruce E. Gerhardt | 男 | Director | 70 | 3.65万美元 | 未持股 | 2021-04-30 |
| Michael W. Nall | 男 | Director, Chief Executive Officer and President | 58 | 178.34万美元 | 未持股 | 2021-04-30 |
| Ivor Royston | 男 | Director | 76 | 3.90万美元 | 未持股 | 2021-04-30 |
| M. Faye Wilson | 女 | Interim Chair | 83 | 5.40万美元 | 未持股 | 2021-04-30 |
| Samuel D. Riccitelli | 男 | Director | 62 | 4.40万美元 | 未持股 | 2021-04-30 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Timothy C. Kennedy | 男 | Chief Financial Officer, Chief Operating Officer and Corporate Secretary | 63 | 110.08万美元 | 未持股 | 2021-04-30 |
| Michael Terry | 男 | Senior Vice President, Corporate Development | 66 | 51.52万美元 | 未持股 | 2021-04-30 |
| Michael C. Dugan | 男 | Senior Vice President, Chief Medical Officer and Medical Director | 59 | 未披露 | 未持股 | 2021-04-30 |
| David F. Hale | 男 | Executive Chairman | 72 | 10.02万美元 | 未持股 | 2021-04-30 |
| Michael W. Nall | 男 | Director, Chief Executive Officer and President | 58 | 178.34万美元 | 未持股 | 2021-04-30 |
董事简历
中英对照 | 中文 | 英文- David F. Hale
-
David F. Hale, 2011年3月被任命为BIOCEPT公司执行董事长。截至2014年2月10日BIOCEPT INC首次公开发行(ipo)完成并与此相关，他曾担任BIOCEPT INC非执行主席至2020年10月。他是Hale BioPharma Ventures LLC(一家专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展的私人公司)的董事长兼首席执行官。他是一名连续企业家，参与了许多生命科学公司的创立和/或发展。自2004年以来，他担任Santarus, Inc.(或Santarus，一家专业生物制药公司)的董事长;自2000年以来，担任Santarus的董事会成员(2014年被Salix Pharmaceuticals, Ltd.收购)。他还曾担任Conatus Pharmaceuticals, Inc.的董事长，直到该公司于2020年与Histogen合并。他曾担任CancerVax Corporation的总裁兼首席执行官(从1999年10月到2006年5月与Micromet, Inc.合并)，当时他成为合并后公司的董事长，直到该公司被Merck & Co.收购。他是Somaxon Pharmaceuticals, Inc.(被Pernix Therapeutics Holdings, Inc.收购)的联合创始人兼董事长，以及SkinMedica, Inc.(被Allergan, Inc.收购)的董事长。他还担任Adigica Health, Inc.、Zerigo Health, Inc.、Neurana Pharmaceuticals, Inc.和Dermata, LLC的董事长，以及Recros Medica, Inc.和Neurelis, Inc.的董事会成员。他曾担任Hybritech, Inc.(第一家单克隆抗体公司，自1982年起被Eli Lilly and Co.收购)的首席运营官、总裁兼首席执行官。从1987年到1997年，他担任Gensia, Inc.(与SICOR合并成为Gensia SICOR, Inc.)的董事长、总裁兼首席执行官，Gensia SICOR, Inc.后来被Teva Pharmaceuticals收购。1987年至1995年，他是Viagene, Inc.的联合创始人兼董事长，当时Viagene被Chiron, Inc.收购。1998年至1999年6月，他担任Women First HealthCare, Inc.的总裁兼首席执行官，1999年10月加入CancerVax。在加入Hybritech之前，他曾担任Becton, Dickinson & Co.的诊断部门BBL Microbiology Systems的副总裁兼总经理，从1971年到1980年，他曾担任Ortho Pharmaceutical Corporation (Johnson & Johnson, Inc.的一个部门)的各种营销和销售管理职位。
David F. Hale was appointed as BIOCEPT INC Executive Chairman in March 2011. As of and in connection with the closing of BIOCEPT INC initial public offering on February 10 2014 Mr. Hale served as BIOCEPT INC non-executive chairman through October 2020. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., or Santarus, a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000 prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also served as Chairman of Conatus Pharmaceuticals, Inc. until its merger with Histogen in 2020 and serves as Chairman of Oncternal Therapeutics, Inc. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined company until its acquisition by Merck & Co. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Zerigo Health, Inc., Neurana Pharmaceuticals, Inc., and Dermata, LLC and is on the board of Recros Medica, Inc. and Neurelis, Inc. He served as COO, President and Chief Executive Officer of Hybritech, Inc., the first monoclonal antibody company, from 1982 it was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995 when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from 1998 to June 1999 before joining CancerVax in October 1999. Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a diagnostics division of Becton, Dickinson & Co. and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc. - David F. Hale, 2011年3月被任命为BIOCEPT公司执行董事长。截至2014年2月10日BIOCEPT INC首次公开发行(ipo)完成并与此相关，他曾担任BIOCEPT INC非执行主席至2020年10月。他是Hale BioPharma Ventures LLC(一家专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展的私人公司)的董事长兼首席执行官。他是一名连续企业家，参与了许多生命科学公司的创立和/或发展。自2004年以来，他担任Santarus, Inc.(或Santarus，一家专业生物制药公司)的董事长;自2000年以来，担任Santarus的董事会成员(2014年被Salix Pharmaceuticals, Ltd.收购)。他还曾担任Conatus Pharmaceuticals, Inc.的董事长，直到该公司于2020年与Histogen合并。他曾担任CancerVax Corporation的总裁兼首席执行官(从1999年10月到2006年5月与Micromet, Inc.合并)，当时他成为合并后公司的董事长，直到该公司被Merck & Co.收购。他是Somaxon Pharmaceuticals, Inc.(被Pernix Therapeutics Holdings, Inc.收购)的联合创始人兼董事长，以及SkinMedica, Inc.(被Allergan, Inc.收购)的董事长。他还担任Adigica Health, Inc.、Zerigo Health, Inc.、Neurana Pharmaceuticals, Inc.和Dermata, LLC的董事长，以及Recros Medica, Inc.和Neurelis, Inc.的董事会成员。他曾担任Hybritech, Inc.(第一家单克隆抗体公司，自1982年起被Eli Lilly and Co.收购)的首席运营官、总裁兼首席执行官。从1987年到1997年，他担任Gensia, Inc.(与SICOR合并成为Gensia SICOR, Inc.)的董事长、总裁兼首席执行官，Gensia SICOR, Inc.后来被Teva Pharmaceuticals收购。1987年至1995年，他是Viagene, Inc.的联合创始人兼董事长，当时Viagene被Chiron, Inc.收购。1998年至1999年6月，他担任Women First HealthCare, Inc.的总裁兼首席执行官，1999年10月加入CancerVax。在加入Hybritech之前，他曾担任Becton, Dickinson & Co.的诊断部门BBL Microbiology Systems的副总裁兼总经理，从1971年到1980年，他曾担任Ortho Pharmaceutical Corporation (Johnson & Johnson, Inc.的一个部门)的各种营销和销售管理职位。
- David F. Hale was appointed as BIOCEPT INC Executive Chairman in March 2011. As of and in connection with the closing of BIOCEPT INC initial public offering on February 10 2014 Mr. Hale served as BIOCEPT INC non-executive chairman through October 2020. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., or Santarus, a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000 prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also served as Chairman of Conatus Pharmaceuticals, Inc. until its merger with Histogen in 2020 and serves as Chairman of Oncternal Therapeutics, Inc. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined company until its acquisition by Merck & Co. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Zerigo Health, Inc., Neurana Pharmaceuticals, Inc., and Dermata, LLC and is on the board of Recros Medica, Inc. and Neurelis, Inc. He served as COO, President and Chief Executive Officer of Hybritech, Inc., the first monoclonal antibody company, from 1982 it was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995 when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from 1998 to June 1999 before joining CancerVax in October 1999. Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a diagnostics division of Becton, Dickinson & Co. and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.
- Marsha A. Chandler
-
Marsha A. Chandler，2007年开始在索尔克生物研究所担任执行副总裁/首席运营官。她管理着大约1000个科学、行政人员和监督所有机构财政、行政和筹款活动。1997年到2007年，她担任加州大学圣地亚哥分校学术事务的高级副总理，她是学术总监。她从2003年至2004年担任代理总理，被任命为国际关系研究生院和太平洋研究UCSD政治学教授。她还是加拿大皇家学会的成员，被授予了那个国家的最高学术荣誉。她持有北卡罗莱纳大学教堂山分校博士学位。
Marsha A. Chandler is Senior Vice Chancellor and Professor Emerita at the School of Global Policy and Strategy at the University of California, San Diego UCSD. She is also currently an Advisor to the College of Health, Lehigh University and Advisor to the Jackson School of Geosciences, and Texas Global at the University of Texas at Austin. Dr. Chandler is also a member of the Board of Directors of the Corporate Directors Forum. She served as the Executive Vice-President and Chief Operating Officer of the Salk Institute for Biological Studies from 2007 to 2015 where she managed approximately 1000 scientific and administrative personnel and oversaw all institutional fiscal, administrative and fund-raising activities. From 1997 to 2007 she was the Senior Vice Chancellor for Academic Affairs at UCSD, where she was the chief academic officer responsible for the policies and decisions relating to research and teaching programs, faculty appointments and performance, and the fiscal, human resources and facilities functions on the general campus. Dr. Chandler is a Fellow of the Royal Society of Canada. She received her Ph.D. from The University of North Carolina at Chapel Hill. In 2004 she completed the Advanced Management Program at Harvard Business School. - Marsha A. Chandler，2007年开始在索尔克生物研究所担任执行副总裁/首席运营官。她管理着大约1000个科学、行政人员和监督所有机构财政、行政和筹款活动。1997年到2007年，她担任加州大学圣地亚哥分校学术事务的高级副总理，她是学术总监。她从2003年至2004年担任代理总理，被任命为国际关系研究生院和太平洋研究UCSD政治学教授。她还是加拿大皇家学会的成员，被授予了那个国家的最高学术荣誉。她持有北卡罗莱纳大学教堂山分校博士学位。
- Marsha A. Chandler is Senior Vice Chancellor and Professor Emerita at the School of Global Policy and Strategy at the University of California, San Diego UCSD. She is also currently an Advisor to the College of Health, Lehigh University and Advisor to the Jackson School of Geosciences, and Texas Global at the University of Texas at Austin. Dr. Chandler is also a member of the Board of Directors of the Corporate Directors Forum. She served as the Executive Vice-President and Chief Operating Officer of the Salk Institute for Biological Studies from 2007 to 2015 where she managed approximately 1000 scientific and administrative personnel and oversaw all institutional fiscal, administrative and fund-raising activities. From 1997 to 2007 she was the Senior Vice Chancellor for Academic Affairs at UCSD, where she was the chief academic officer responsible for the policies and decisions relating to research and teaching programs, faculty appointments and performance, and the fiscal, human resources and facilities functions on the general campus. Dr. Chandler is a Fellow of the Royal Society of Canada. She received her Ph.D. from The University of North Carolina at Chapel Hill. In 2004 she completed the Advanced Management Program at Harvard Business School.
- Bruce E. Gerhardt
-
Bruce E. Gerhardt，1986年开始担任自由职业者，执业注册会计师。他也是为小企业提供税收遵从和高收入的个人业务的税收和商业顾问。1973年，他持有南加州大学文学士学位，是美国注册会计师协会的一员。
Bruce E. Gerhardt has been self-employed, practicing as a Certified Public Accountant, since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. Prior to 1986 he was a financial vice-president with several companies and a senior accountant with Peat Marwick Mitchell, now KPMG. He earned his B.A. from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants. - Bruce E. Gerhardt，1986年开始担任自由职业者，执业注册会计师。他也是为小企业提供税收遵从和高收入的个人业务的税收和商业顾问。1973年，他持有南加州大学文学士学位，是美国注册会计师协会的一员。
- Bruce E. Gerhardt has been self-employed, practicing as a Certified Public Accountant, since 1986. He is also a tax and business advisor providing tax compliance for small businesses and upper income individuals. Prior to 1986 he was a financial vice-president with several companies and a senior accountant with Peat Marwick Mitchell, now KPMG. He earned his B.A. from the University of Southern California in 1973 and is a member of the American Institute of Certified Public Accountants.
- Michael W. Nall
-
Michael W. Nall，拥有超过25年的医疗销售或市场营销经验，最近在Clarient Diagnostic Services公司就职，从2002年到2013年8月担任北美销售和营销总经理，他在该公司的职位越来越高。在Clarient，他负责领导团队吸收Clarient集团（在2010年，Clarient后被通用电气医疗集团收购了）。从1988年到加入Clarient集团，他曾在诊断和医疗设备行业担任过各种商业领导角色，包括Impath公司、American Cyanamid 公司、Maquet Surgical公司、Strato Medical 公司、Horizon Medical Products公司、哥伦比亚Vital Systems公司。他持有中央密苏里州立大学（现在被称为中央密苏里大学）工商管理学士学位。
Michael W. Nall has over 30 years of healthcare sales and marketing experience and has served as our CEO and President since 2013. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc., or Clarient, in positions of increasing responsibility from 2002 through August 2013 with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010.From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems.Mr. Nall received a B.S. in Business Administration from Central Missouri State University now known as the University of Central Missouri. - Michael W. Nall，拥有超过25年的医疗销售或市场营销经验，最近在Clarient Diagnostic Services公司就职，从2002年到2013年8月担任北美销售和营销总经理，他在该公司的职位越来越高。在Clarient，他负责领导团队吸收Clarient集团（在2010年，Clarient后被通用电气医疗集团收购了）。从1988年到加入Clarient集团，他曾在诊断和医疗设备行业担任过各种商业领导角色，包括Impath公司、American Cyanamid 公司、Maquet Surgical公司、Strato Medical 公司、Horizon Medical Products公司、哥伦比亚Vital Systems公司。他持有中央密苏里州立大学（现在被称为中央密苏里大学）工商管理学士学位。
- Michael W. Nall has over 30 years of healthcare sales and marketing experience and has served as our CEO and President since 2013. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc., or Clarient, in positions of increasing responsibility from 2002 through August 2013 with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010.From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems.Mr. Nall received a B.S. in Business Administration from Central Missouri State University now known as the University of Central Missouri.
- Ivor Royston
-
Ivor Royston，2000年开始担任Forward Ventures企业合伙人。1990年到2000年，他担任The Sidney Kimmel Cancer Center集团创世总裁兼首席执行官。1978年到1990年，他是加州大学圣地亚哥分校肿瘤学教授。除了Hybritech的创始人之一，1986年，他创办IDEC公司，后来与生原体形成BiogenIdec合并。Royston博士对众多生物技术公司的融资和发展起到了重要作用，包括Applied Molecular Evolution集团被Eli Lilly集团收购，Corixa（被葛兰素史克公司收购），Dynavax,LigoCyte（被武田收购），Morphotek卫材（收购），Sequana疗法（Celera收购），TargeGen（赛诺菲-安万特收购），和三角制药（基列收购）。他目前是MMRGlobal公司（上市医疗记录管理公司）董事。他持有约翰霍普金斯大学学士学位，内科和斯坦福大学医学肿瘤学医学博士学位，完成博士后培训。1997年克林顿总统任命为他在全国癌症咨询委员会就职，任期6年。
Ivor Royston currently serves as CEO of Viracta Therapeutics, Inc., or Viracta. From 1990 to 2000 he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990 he was a member of the oncology faculty of the University of California, San Diego. In addition to being a co-founder of Hybritech, Inc., in 1986 he co-founded IDEC Corporation, which later merged with Biogen to form Biogen Idec. From 1990 to 2017 Dr. Royston was the Founding Managing Partner of Forward Ventures and has been instrumental in the formation, financing and development of numerous biotechnology companies. He is currently a director of Viracta. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997 President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board. - Ivor Royston，2000年开始担任Forward Ventures企业合伙人。1990年到2000年，他担任The Sidney Kimmel Cancer Center集团创世总裁兼首席执行官。1978年到1990年，他是加州大学圣地亚哥分校肿瘤学教授。除了Hybritech的创始人之一，1986年，他创办IDEC公司，后来与生原体形成BiogenIdec合并。Royston博士对众多生物技术公司的融资和发展起到了重要作用，包括Applied Molecular Evolution集团被Eli Lilly集团收购，Corixa（被葛兰素史克公司收购），Dynavax,LigoCyte（被武田收购），Morphotek卫材（收购），Sequana疗法（Celera收购），TargeGen（赛诺菲-安万特收购），和三角制药（基列收购）。他目前是MMRGlobal公司（上市医疗记录管理公司）董事。他持有约翰霍普金斯大学学士学位，内科和斯坦福大学医学肿瘤学医学博士学位，完成博士后培训。1997年克林顿总统任命为他在全国癌症咨询委员会就职，任期6年。
- Ivor Royston currently serves as CEO of Viracta Therapeutics, Inc., or Viracta. From 1990 to 2000 he served as founding President and CEO of The Sidney Kimmel Cancer Center and from 1978 to 1990 he was a member of the oncology faculty of the University of California, San Diego. In addition to being a co-founder of Hybritech, Inc., in 1986 he co-founded IDEC Corporation, which later merged with Biogen to form Biogen Idec. From 1990 to 2017 Dr. Royston was the Founding Managing Partner of Forward Ventures and has been instrumental in the formation, financing and development of numerous biotechnology companies. He is currently a director of Viracta. Dr. Royston received his B.A. and M.D. degrees from Johns Hopkins University and completed post-doctoral training in internal medicine and medical oncology at Stanford University. In 1997 President Clinton appointed Dr. Royston to a six-year term on the National Cancer Advisory Board.
- M. Faye Wilson
-
M. Faye Wilson，2003年开始在Wilson Boyles & Co。公司（业务管理和战略规划咨询公司）担任总裁。她也是BioMed Realty Trust公司（不动产信托公司房地产投资信托基金）董事会成员。1992年到1998年，她曾在农民保险集团公司董事会，1991年到2001年加入家得宝（Home Depot）go公司董事会。1998年到2002年，她也是家得宝（Home Depot）公司的高级官员。1992年到1998年，她曾在美国银行（Bank of America）公司担任过几个高级管理职位，包括安全太平洋金融服务主席，银行执行副总裁兼首席信贷官，国家消费者的银行集团。她持有南加州大学国际关系学位和工商管理，杜克大学的本科学位。
M. Faye Wilson is retired CEO of Wilson Boyles and Company, a business consulting firm specializing in the development and implementation of successful business strategies. Prior to co-founding Wilson Boyles in 2003 she served as Senior Vice-President, Value Initiatives and Risk Management for The Home Depot, having joined the company in 1998 following a 21-year career at Bank of America. Ms. Wilson was Executive-Vice President of Bank of America and Chairman and President of Security Pacific Financial Services, a wholly owned subsidiary of BancAmerica Corporation.Ms. Wilson began her banking career as a management trainee in the Corporate Banking Group of Security Pacific National Bank, which merged with and became Bank of America in 1992. Prior to assuming the chairmanship of Security Pacific Financial Services, she was the Executive Vice-President responsible for overseeing credit quality and policy for over 80 of Bank of America's loan portfolio.During her Security Pacific career, Ms. Wilson spent time in London as the Managing Director of Corporate Finance for Security Pacific Hoare Govett, where she created new corporate advisory services, debt structuring products and formed a cross-border mergers and acquisitions division for European and U.S. companies. Prior to the London assignment, she was Managing Director of the Leveraged Buyout Group for the Security Pacific Merchant Bank. Earlier, Ms. Wilson served as Senior Vice-President and Regional Manager in the Corporate Banking Division with responsibility for multinational corporations, retail industry companies and California based corporations.Ms. Wilson has served as a director on the boards of BioMed Realty Trust, Inc., a real estate investment trust, until its acquisition by Blackstone Real Estate Partners VIII in 2016 Farmers Insurance Group, The Home Depot, SKM, a Russian public company, Community National Bank and trustee of The Salk Institute. Currently she serves as Chair of the Audit Committee of Sharp Health Group and IQHQ REIT.Ms. Wilson received master's degrees in international relations and in business administration from the University of Southern California. - M. Faye Wilson，2003年开始在Wilson Boyles & Co。公司（业务管理和战略规划咨询公司）担任总裁。她也是BioMed Realty Trust公司（不动产信托公司房地产投资信托基金）董事会成员。1992年到1998年，她曾在农民保险集团公司董事会，1991年到2001年加入家得宝（Home Depot）go公司董事会。1998年到2002年，她也是家得宝（Home Depot）公司的高级官员。1992年到1998年，她曾在美国银行（Bank of America）公司担任过几个高级管理职位，包括安全太平洋金融服务主席，银行执行副总裁兼首席信贷官，国家消费者的银行集团。她持有南加州大学国际关系学位和工商管理，杜克大学的本科学位。
- M. Faye Wilson is retired CEO of Wilson Boyles and Company, a business consulting firm specializing in the development and implementation of successful business strategies. Prior to co-founding Wilson Boyles in 2003 she served as Senior Vice-President, Value Initiatives and Risk Management for The Home Depot, having joined the company in 1998 following a 21-year career at Bank of America. Ms. Wilson was Executive-Vice President of Bank of America and Chairman and President of Security Pacific Financial Services, a wholly owned subsidiary of BancAmerica Corporation.Ms. Wilson began her banking career as a management trainee in the Corporate Banking Group of Security Pacific National Bank, which merged with and became Bank of America in 1992. Prior to assuming the chairmanship of Security Pacific Financial Services, she was the Executive Vice-President responsible for overseeing credit quality and policy for over 80 of Bank of America's loan portfolio.During her Security Pacific career, Ms. Wilson spent time in London as the Managing Director of Corporate Finance for Security Pacific Hoare Govett, where she created new corporate advisory services, debt structuring products and formed a cross-border mergers and acquisitions division for European and U.S. companies. Prior to the London assignment, she was Managing Director of the Leveraged Buyout Group for the Security Pacific Merchant Bank. Earlier, Ms. Wilson served as Senior Vice-President and Regional Manager in the Corporate Banking Division with responsibility for multinational corporations, retail industry companies and California based corporations.Ms. Wilson has served as a director on the boards of BioMed Realty Trust, Inc., a real estate investment trust, until its acquisition by Blackstone Real Estate Partners VIII in 2016 Farmers Insurance Group, The Home Depot, SKM, a Russian public company, Community National Bank and trustee of The Salk Institute. Currently she serves as Chair of the Audit Committee of Sharp Health Group and IQHQ REIT.Ms. Wilson received master's degrees in international relations and in business administration from the University of Southern California.
- Samuel D. Riccitelli
-
Samuel D. Riccitelli，2012年10月起担任公司总裁、首席执行官、董事会成员。2011年7月至2012年10月，他担任独立顾问。2001年10月至2011年6月，他担任Genoptix, Inc.执行副总裁和首席运营官，该公司是一家上市诊断服务公司，关注社区血液学家和肿瘤学家的需求。1995至2001年，他在Becton, Dickinson and Company担任多个职位，包括最近一职是副总裁和总经理，以及风险投资基金BD Ventures, L.L.C.董事会成员。1989至1994年，他在Puritan-Bennett Corporation担任多个职位，包括最近一职是总经理。他也是Exagen Diagnostics, Inc.董事会成员，自2011年10月起任董事。他获有Washington and Jefferson College生物学学士学位，以及University of Texas机械和生物医学工程专业工程硕士学位。
Samuel D. Riccitelli has been in the healthcare industry for more than 35 years. He has served as a member of the Board of Directors of Orthopediatrics, Inc. since 2017 a company focused exclusively on the orthopedic implant needs of children. He recently served as Chief Executive Officer of Pathnostics, LLC, a molecular diagnostics company focused on improving antibiotic stewardship, from 2019 to 2020. From 2017 to 2019 Mr. Riccitelli served as Chairman of the Board of Directors of Precipio, Inc., a diagnostic services company. From 2012 to 2017 Mr. Riccitelli served as President and Chief Executive Officer and a Director of Signal Genetics, Inc., a publicly traded molecular diagnostic company that was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic company that was sold to Novartis in 2011. Mr. Riccitelli served in a number of research and development and general management leadership positions for Becton, Dickinson and Company and as a vice president, general manager and board member for BD Ventures, LLC., a venture capital fund. Mr. Riccitelli received a B.A. from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas. - Samuel D. Riccitelli，2012年10月起担任公司总裁、首席执行官、董事会成员。2011年7月至2012年10月，他担任独立顾问。2001年10月至2011年6月，他担任Genoptix, Inc.执行副总裁和首席运营官，该公司是一家上市诊断服务公司，关注社区血液学家和肿瘤学家的需求。1995至2001年，他在Becton, Dickinson and Company担任多个职位，包括最近一职是副总裁和总经理，以及风险投资基金BD Ventures, L.L.C.董事会成员。1989至1994年，他在Puritan-Bennett Corporation担任多个职位，包括最近一职是总经理。他也是Exagen Diagnostics, Inc.董事会成员，自2011年10月起任董事。他获有Washington and Jefferson College生物学学士学位，以及University of Texas机械和生物医学工程专业工程硕士学位。
- Samuel D. Riccitelli has been in the healthcare industry for more than 35 years. He has served as a member of the Board of Directors of Orthopediatrics, Inc. since 2017 a company focused exclusively on the orthopedic implant needs of children. He recently served as Chief Executive Officer of Pathnostics, LLC, a molecular diagnostics company focused on improving antibiotic stewardship, from 2019 to 2020. From 2017 to 2019 Mr. Riccitelli served as Chairman of the Board of Directors of Precipio, Inc., a diagnostic services company. From 2012 to 2017 Mr. Riccitelli served as President and Chief Executive Officer and a Director of Signal Genetics, Inc., a publicly traded molecular diagnostic company that was ultimately sold to Miragen Therapeutics, Inc. Mr. Riccitelli was also previously the Executive Vice President and Chief Operating Officer of Genoptix, Inc., a publicly traded diagnostic company that was sold to Novartis in 2011. Mr. Riccitelli served in a number of research and development and general management leadership positions for Becton, Dickinson and Company and as a vice president, general manager and board member for BD Ventures, LLC., a venture capital fund. Mr. Riccitelli received a B.A. from Washington and Jefferson College and a M.S. Engineering degree from The University of Texas.
高管简历
中英对照 | 中文 | 英文- Timothy C. Kennedy
TimothyC.Kennedy于2016年7月加入我们，担任运营高级副总裁兼公司秘书首席财务官。Kennedy先生曾于2013年至2016年7月担任Millennium Health（一家私人控股的领先尿液药物检测和药物遗传学实验室公司）的首席财务官。加入Millennium Health之前，Kennedy从2008年到2012年担任Plus Diagnostics（一家泌尿外科、胃肠病学和肿瘤学实验室）首席财务官和总经理。加入Plus Diagnostics之前，Kennedy从1997年到2008年在Diagnostic Imaging Management（一家多站点成像公司，在美国从12个独立中心扩展到33个独立中心）担任所有权职位。从1988年到1997年，他曾担任National Health Laboratories公司的多种管理职务，在那里他曾担任财务主管，在那里他曾完成50多次收购，并于1995年与Roche Biomedical Laboratories公司合并，形成LabCorp公司。Kennedy先生是MyCircle Health公司的董事，该公司是一家数据服务公司，帮助患有慢性疾病的患者测量、评估、控制并向他们的梦百合提供者和医生传达日常测试结果。Kennedy先生拥有Keane University商业会计/信息技术学士学位。
Timothy C. Kennedy joined us as Chief Financial Officer, Senior Vice-President of Operations and Corporate Secretary in July 2016 and has also served as our Chief Operating Officer since January 2021. Mr. Kennedy has over 30 years of executive, financial, and operational leadership experience, with over 25 years in the clinical diagnostics industry. Mr. Kennedy previously served as Chief Financial Officer of Millennium Health, a privately held leading urine drug testing and pharmacogenetics laboratory company, from 2013 to July 2016. Prior to joining Millennium Health, Mr. Kennedy was Chief Financial Officer and General Manager of PLUS Diagnostics, a urology, gastroenterology and oncology lab from 2008 through 2012. Prior to Plus Diagnostics, Mr. Kennedy held an ownership position in Diagnostic Imaging Management, a multi-site imaging company from 1997 to 2008 expanding from 12 to 33 free-standing centers across the United States. From 1988 to 1997 Mr. Kennedy held a number of management positions with National Health Laboratories, where he served as the Head of Finance. Mr. Kennedy holds a B.S in Business - Accounting/Information Technology from Keane University.- TimothyC.Kennedy于2016年7月加入我们，担任运营高级副总裁兼公司秘书首席财务官。Kennedy先生曾于2013年至2016年7月担任Millennium Health（一家私人控股的领先尿液药物检测和药物遗传学实验室公司）的首席财务官。加入Millennium Health之前，Kennedy从2008年到2012年担任Plus Diagnostics（一家泌尿外科、胃肠病学和肿瘤学实验室）首席财务官和总经理。加入Plus Diagnostics之前，Kennedy从1997年到2008年在Diagnostic Imaging Management（一家多站点成像公司，在美国从12个独立中心扩展到33个独立中心）担任所有权职位。从1988年到1997年，他曾担任National Health Laboratories公司的多种管理职务，在那里他曾担任财务主管，在那里他曾完成50多次收购，并于1995年与Roche Biomedical Laboratories公司合并，形成LabCorp公司。Kennedy先生是MyCircle Health公司的董事，该公司是一家数据服务公司，帮助患有慢性疾病的患者测量、评估、控制并向他们的梦百合提供者和医生传达日常测试结果。Kennedy先生拥有Keane University商业会计/信息技术学士学位。
- Timothy C. Kennedy joined us as Chief Financial Officer, Senior Vice-President of Operations and Corporate Secretary in July 2016 and has also served as our Chief Operating Officer since January 2021. Mr. Kennedy has over 30 years of executive, financial, and operational leadership experience, with over 25 years in the clinical diagnostics industry. Mr. Kennedy previously served as Chief Financial Officer of Millennium Health, a privately held leading urine drug testing and pharmacogenetics laboratory company, from 2013 to July 2016. Prior to joining Millennium Health, Mr. Kennedy was Chief Financial Officer and General Manager of PLUS Diagnostics, a urology, gastroenterology and oncology lab from 2008 through 2012. Prior to Plus Diagnostics, Mr. Kennedy held an ownership position in Diagnostic Imaging Management, a multi-site imaging company from 1997 to 2008 expanding from 12 to 33 free-standing centers across the United States. From 1988 to 1997 Mr. Kennedy held a number of management positions with National Health Laboratories, where he served as the Head of Finance. Mr. Kennedy holds a B.S in Business - Accounting/Information Technology from Keane University.
- Michael Terry
Michael Terry于2017年2月加入我们，担任商业运营高级副总裁。特里在分子诊断和液体活检行业经验丰富，此前曾于2012年至2014年担任Trovagene，Inc.的执行Vice President、商业运营和企业发展，以及Sequenom，Inc.的执行Vice President，在那里他从2003年到2005年管理全球商业运营。Terry先生的职业生涯还包括在GE梦百合Marquette Medical Division工作4年，从1997年到2001年，他在该公司担任销售管理、商业运营和电子商务方面的关键执行职位。在通用电气梦百合，他获得了六西格玛认证。Terry先生还担任LumenisLtd.欧洲业务的执行Vice President、Aspect Medical Systems Inc.全球销售的Vice President以及Ligand Diagnostics的首席执行官。Terry先生在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得经济学和商学学士学位。
Michael Terry joined us as Senior Vice-President of Commercial Operations in February 2017. Mr. Terry has previously served as Executive Vice President, Commercial Operations and Corporate Development of Trovagene, Inc. from 2012 to 2014 as well as Executive Vice President of Sequenom, Inc., where he managed global commercial operations from 2003 to 2005. Mr. Terry's career also includes four years at GE Healthcare's Marquette Medical division, where he held executive positions in sales management, commercial operations and eBusiness from 1997 to 2001. Mr. Terry has also served as the Executive Vice President of European Operations for Lumenis Ltd., Vice President of Global Sales for Aspect Medical Systems Inc., and Chief Executive Officer of Ligand Diagnostics. Mr. Terry earned a B.S. in Economics and Business from the University of Wisconsin - Madison.- Michael Terry于2017年2月加入我们，担任商业运营高级副总裁。特里在分子诊断和液体活检行业经验丰富，此前曾于2012年至2014年担任Trovagene，Inc.的执行Vice President、商业运营和企业发展，以及Sequenom，Inc.的执行Vice President，在那里他从2003年到2005年管理全球商业运营。Terry先生的职业生涯还包括在GE梦百合Marquette Medical Division工作4年，从1997年到2001年，他在该公司担任销售管理、商业运营和电子商务方面的关键执行职位。在通用电气梦百合，他获得了六西格玛认证。Terry先生还担任LumenisLtd.欧洲业务的执行Vice President、Aspect Medical Systems Inc.全球销售的Vice President以及Ligand Diagnostics的首席执行官。Terry先生在威斯康星大学麦迪逊分校（University of Wisconsin-Madison）获得经济学和商学学士学位。
- Michael Terry joined us as Senior Vice-President of Commercial Operations in February 2017. Mr. Terry has previously served as Executive Vice President, Commercial Operations and Corporate Development of Trovagene, Inc. from 2012 to 2014 as well as Executive Vice President of Sequenom, Inc., where he managed global commercial operations from 2003 to 2005. Mr. Terry's career also includes four years at GE Healthcare's Marquette Medical division, where he held executive positions in sales management, commercial operations and eBusiness from 1997 to 2001. Mr. Terry has also served as the Executive Vice President of European Operations for Lumenis Ltd., Vice President of Global Sales for Aspect Medical Systems Inc., and Chief Executive Officer of Ligand Diagnostics. Mr. Terry earned a B.S. in Economics and Business from the University of Wisconsin - Madison.
- Michael C. Dugan
Michael C.Dugan于2020年8月加入我们，担任高级副总裁，首席医疗官兼医疗总监。Dugan博士作为首席营销官领导我们的临床战略发展，并作为医学总监监督我们CAP认证的CLIA临床实验室。他是一位经验丰富的内科医生和生物技术执行官，曾指导几个主要的商业参考实验室，并帮助推出了许多新的分子诊断分析和平台，这些分析和平台用于肿瘤，传染病和公共卫生应用，例如癌症筛查，监测，诊断和治疗选择。Dugan博士曾在Clinical Genomics，Exact Sciences，Genzyme Genetics，Quest Diagnostics（包括被收购的公司Ameripath和Specialty Laboratories）和UCLA担任领导职务。他毕业于圣母大学，在那里他获得了生物学学士学位和亚利桑那大学医学院，他在耶鲁大学纽黑文医院完成了解剖病理学的研究生医学教育，并在洛杉矶儿童医院和加州大学洛杉矶分校继续接受病理学和实验室医学的培训。他获得了解剖学和临床病理学的委员会认证。
Michael C. Dugan joined us as Senior Vice President, Chief Medical Officer and Medical Director in August 2020. Dr. Dugan leads our clinical strategic development as CMO and oversees our CAP accredited CLIA clinical laboratory as Medical Director. He is an experienced physician and biotech executive who has directed several major commercial reference laboratories and helped launch numerous novel molecular diagnostic assays and platforms used in oncology, infectious disease and public health applications such as cancer screening, monitoring, diagnosis and therapy selection. Dr. Dugan has held leadership positions with Clinical Genomics, Exact Sciences, Genzyme Genetics acquired by LabCorp, Quest Diagnostics (including acquired companies AmeriPath and Specialty Laboratories), and UCLA. A graduate of the University of Notre Dame where he received a B.S. in Biology and University of Arizona College of Medicine, he completed his post-graduate medical education in anatomic pathology at Yale-New Haven Hospital and continued training in pathology and laboratory medicine at Children's Hospital Los Angeles and UCLA. He is board-certified in Anatomic and Clinical Pathology.- Michael C.Dugan于2020年8月加入我们，担任高级副总裁，首席医疗官兼医疗总监。Dugan博士作为首席营销官领导我们的临床战略发展，并作为医学总监监督我们CAP认证的CLIA临床实验室。他是一位经验丰富的内科医生和生物技术执行官，曾指导几个主要的商业参考实验室，并帮助推出了许多新的分子诊断分析和平台，这些分析和平台用于肿瘤，传染病和公共卫生应用，例如癌症筛查，监测，诊断和治疗选择。Dugan博士曾在Clinical Genomics，Exact Sciences，Genzyme Genetics，Quest Diagnostics（包括被收购的公司Ameripath和Specialty Laboratories）和UCLA担任领导职务。他毕业于圣母大学，在那里他获得了生物学学士学位和亚利桑那大学医学院，他在耶鲁大学纽黑文医院完成了解剖病理学的研究生医学教育，并在洛杉矶儿童医院和加州大学洛杉矶分校继续接受病理学和实验室医学的培训。他获得了解剖学和临床病理学的委员会认证。
- Michael C. Dugan joined us as Senior Vice President, Chief Medical Officer and Medical Director in August 2020. Dr. Dugan leads our clinical strategic development as CMO and oversees our CAP accredited CLIA clinical laboratory as Medical Director. He is an experienced physician and biotech executive who has directed several major commercial reference laboratories and helped launch numerous novel molecular diagnostic assays and platforms used in oncology, infectious disease and public health applications such as cancer screening, monitoring, diagnosis and therapy selection. Dr. Dugan has held leadership positions with Clinical Genomics, Exact Sciences, Genzyme Genetics acquired by LabCorp, Quest Diagnostics (including acquired companies AmeriPath and Specialty Laboratories), and UCLA. A graduate of the University of Notre Dame where he received a B.S. in Biology and University of Arizona College of Medicine, he completed his post-graduate medical education in anatomic pathology at Yale-New Haven Hospital and continued training in pathology and laboratory medicine at Children's Hospital Los Angeles and UCLA. He is board-certified in Anatomic and Clinical Pathology.
- David F. Hale
David F. Hale, 2011年3月被任命为BIOCEPT公司执行董事长。截至2014年2月10日BIOCEPT INC首次公开发行(ipo)完成并与此相关，他曾担任BIOCEPT INC非执行主席至2020年10月。他是Hale BioPharma Ventures LLC(一家专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展的私人公司)的董事长兼首席执行官。他是一名连续企业家，参与了许多生命科学公司的创立和/或发展。自2004年以来，他担任Santarus, Inc.(或Santarus，一家专业生物制药公司)的董事长;自2000年以来，担任Santarus的董事会成员(2014年被Salix Pharmaceuticals, Ltd.收购)。他还曾担任Conatus Pharmaceuticals, Inc.的董事长，直到该公司于2020年与Histogen合并。他曾担任CancerVax Corporation的总裁兼首席执行官(从1999年10月到2006年5月与Micromet, Inc.合并)，当时他成为合并后公司的董事长，直到该公司被Merck & Co.收购。他是Somaxon Pharmaceuticals, Inc.(被Pernix Therapeutics Holdings, Inc.收购)的联合创始人兼董事长，以及SkinMedica, Inc.(被Allergan, Inc.收购)的董事长。他还担任Adigica Health, Inc.、Zerigo Health, Inc.、Neurana Pharmaceuticals, Inc.和Dermata, LLC的董事长，以及Recros Medica, Inc.和Neurelis, Inc.的董事会成员。他曾担任Hybritech, Inc.(第一家单克隆抗体公司，自1982年起被Eli Lilly and Co.收购)的首席运营官、总裁兼首席执行官。从1987年到1997年，他担任Gensia, Inc.(与SICOR合并成为Gensia SICOR, Inc.)的董事长、总裁兼首席执行官，Gensia SICOR, Inc.后来被Teva Pharmaceuticals收购。1987年至1995年，他是Viagene, Inc.的联合创始人兼董事长，当时Viagene被Chiron, Inc.收购。1998年至1999年6月，他担任Women First HealthCare, Inc.的总裁兼首席执行官，1999年10月加入CancerVax。在加入Hybritech之前，他曾担任Becton, Dickinson & Co.的诊断部门BBL Microbiology Systems的副总裁兼总经理，从1971年到1980年，他曾担任Ortho Pharmaceutical Corporation (Johnson & Johnson, Inc.的一个部门)的各种营销和销售管理职位。
David F. Hale was appointed as BIOCEPT INC Executive Chairman in March 2011. As of and in connection with the closing of BIOCEPT INC initial public offering on February 10 2014 Mr. Hale served as BIOCEPT INC non-executive chairman through October 2020. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., or Santarus, a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000 prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also served as Chairman of Conatus Pharmaceuticals, Inc. until its merger with Histogen in 2020 and serves as Chairman of Oncternal Therapeutics, Inc. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined company until its acquisition by Merck & Co. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Zerigo Health, Inc., Neurana Pharmaceuticals, Inc., and Dermata, LLC and is on the board of Recros Medica, Inc. and Neurelis, Inc. He served as COO, President and Chief Executive Officer of Hybritech, Inc., the first monoclonal antibody company, from 1982 it was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995 when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from 1998 to June 1999 before joining CancerVax in October 1999. Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a diagnostics division of Becton, Dickinson & Co. and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.- David F. Hale, 2011年3月被任命为BIOCEPT公司执行董事长。截至2014年2月10日BIOCEPT INC首次公开发行(ipo)完成并与此相关，他曾担任BIOCEPT INC非执行主席至2020年10月。他是Hale BioPharma Ventures LLC(一家专注于生物技术、专业制药、诊断和医疗设备公司的形成和发展的私人公司)的董事长兼首席执行官。他是一名连续企业家，参与了许多生命科学公司的创立和/或发展。自2004年以来，他担任Santarus, Inc.(或Santarus，一家专业生物制药公司)的董事长;自2000年以来，担任Santarus的董事会成员(2014年被Salix Pharmaceuticals, Ltd.收购)。他还曾担任Conatus Pharmaceuticals, Inc.的董事长，直到该公司于2020年与Histogen合并。他曾担任CancerVax Corporation的总裁兼首席执行官(从1999年10月到2006年5月与Micromet, Inc.合并)，当时他成为合并后公司的董事长，直到该公司被Merck & Co.收购。他是Somaxon Pharmaceuticals, Inc.(被Pernix Therapeutics Holdings, Inc.收购)的联合创始人兼董事长，以及SkinMedica, Inc.(被Allergan, Inc.收购)的董事长。他还担任Adigica Health, Inc.、Zerigo Health, Inc.、Neurana Pharmaceuticals, Inc.和Dermata, LLC的董事长，以及Recros Medica, Inc.和Neurelis, Inc.的董事会成员。他曾担任Hybritech, Inc.(第一家单克隆抗体公司，自1982年起被Eli Lilly and Co.收购)的首席运营官、总裁兼首席执行官。从1987年到1997年，他担任Gensia, Inc.(与SICOR合并成为Gensia SICOR, Inc.)的董事长、总裁兼首席执行官，Gensia SICOR, Inc.后来被Teva Pharmaceuticals收购。1987年至1995年，他是Viagene, Inc.的联合创始人兼董事长，当时Viagene被Chiron, Inc.收购。1998年至1999年6月，他担任Women First HealthCare, Inc.的总裁兼首席执行官，1999年10月加入CancerVax。在加入Hybritech之前，他曾担任Becton, Dickinson & Co.的诊断部门BBL Microbiology Systems的副总裁兼总经理，从1971年到1980年，他曾担任Ortho Pharmaceutical Corporation (Johnson & Johnson, Inc.的一个部门)的各种营销和销售管理职位。
- David F. Hale was appointed as BIOCEPT INC Executive Chairman in March 2011. As of and in connection with the closing of BIOCEPT INC initial public offering on February 10 2014 Mr. Hale served as BIOCEPT INC non-executive chairman through October 2020. He is the Chairman and CEO of Hale BioPharma Ventures LLC, a private company focused on the formation and development of biotechnology, specialty pharma, diagnostic and medical device companies. Mr. Hale is a serial entrepreneur who has been involved in the founding and/or development of a number of life sciences companies. He served as the Chairman of Santarus, Inc., or Santarus, a specialty biopharmaceutical company, since 2004 and a member of Santarus' board since 2000 prior to its acquisition by Salix Pharmaceuticals, Ltd. in 2014. He also served as Chairman of Conatus Pharmaceuticals, Inc. until its merger with Histogen in 2020 and serves as Chairman of Oncternal Therapeutics, Inc. He was previously President and CEO of CancerVax Corporation from October 1999 through its merger in May 2006 with Micromet, Inc., when he became Chairman of the combined company until its acquisition by Merck & Co. He is a co-founder and served as Chairman of Somaxon Pharmaceuticals, Inc. before its acquisition by Pernix Therapeutics Holdings, Inc., and as Chairman of SkinMedica, Inc., before its acquisition by Allergan, Inc. He also serves as Chairman of Adigica Health, Inc., Zerigo Health, Inc., Neurana Pharmaceuticals, Inc., and Dermata, LLC and is on the board of Recros Medica, Inc. and Neurelis, Inc. He served as COO, President and Chief Executive Officer of Hybritech, Inc., the first monoclonal antibody company, from 1982 it was acquired by Eli Lilly and Co. in 1986. From 1987 until 1997 he was Chairman, President and CEO of Gensia, Inc., which merged with SICOR to become Gensia Sicor, Inc., which was later acquired by Teva Pharmaceuticals. He was a co-founder and Chairman of Viagene, Inc. from 1987 to 1995 when Viagene was acquired by Chiron, Inc. He was President and CEO of Women First HealthCare, Inc. from 1998 to June 1999 before joining CancerVax in October 1999. Prior to joining Hybritech, Mr. Hale was Vice President and General Manager of BBL Microbiology Systems, a diagnostics division of Becton, Dickinson & Co. and from 1971 to 1980 he held various marketing and sales management positions with Ortho Pharmaceutical Corporation, a division of Johnson & Johnson, Inc.
- Michael W. Nall
Michael W. Nall，拥有超过25年的医疗销售或市场营销经验，最近在Clarient Diagnostic Services公司就职，从2002年到2013年8月担任北美销售和营销总经理，他在该公司的职位越来越高。在Clarient，他负责领导团队吸收Clarient集团（在2010年，Clarient后被通用电气医疗集团收购了）。从1988年到加入Clarient集团，他曾在诊断和医疗设备行业担任过各种商业领导角色，包括Impath公司、American Cyanamid 公司、Maquet Surgical公司、Strato Medical 公司、Horizon Medical Products公司、哥伦比亚Vital Systems公司。他持有中央密苏里州立大学（现在被称为中央密苏里大学）工商管理学士学位。
Michael W. Nall has over 30 years of healthcare sales and marketing experience and has served as our CEO and President since 2013. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc., or Clarient, in positions of increasing responsibility from 2002 through August 2013 with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010.From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems.Mr. Nall received a B.S. in Business Administration from Central Missouri State University now known as the University of Central Missouri.- Michael W. Nall，拥有超过25年的医疗销售或市场营销经验，最近在Clarient Diagnostic Services公司就职，从2002年到2013年8月担任北美销售和营销总经理，他在该公司的职位越来越高。在Clarient，他负责领导团队吸收Clarient集团（在2010年，Clarient后被通用电气医疗集团收购了）。从1988年到加入Clarient集团，他曾在诊断和医疗设备行业担任过各种商业领导角色，包括Impath公司、American Cyanamid 公司、Maquet Surgical公司、Strato Medical 公司、Horizon Medical Products公司、哥伦比亚Vital Systems公司。他持有中央密苏里州立大学（现在被称为中央密苏里大学）工商管理学士学位。
- Michael W. Nall has over 30 years of healthcare sales and marketing experience and has served as our CEO and President since 2013. Before joining Biocept, Mr. Nall served at Clarient Diagnostic Services, Inc., or Clarient, in positions of increasing responsibility from 2002 through August 2013 with his last position being General Manager, North American Sales and Marketing. While at Clarient, Mr. Nall was also responsible for leading the team assimilating Clarient into GE Healthcare after Clarient was acquired in 2010.From 1988 until joining Clarient, Mr. Nall served in the diagnostic and medical device industries in various commercial leadership roles for companies including Impath, American Cyanamid, Maquet Surgical, Strato Medical, Horizon Medical Products and Columbia Vital Systems.Mr. Nall received a B.S. in Business Administration from Central Missouri State University now known as the University of Central Missouri.